Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 13/08/2024
• Auteurs : Romain DeschampsJessica GuillaumeJonathan CironBertrand AudoinAurélie RuetÉlisabeth MaillartJulie PiqueLakhdar BenyahyaDavid-Axel LaplaudLaure MichelNicolas CollonguesMikael CohenXavier AyrignacEric ThouvenotHélène ZéphirBertrand BourreCaroline FromentThibault MoreauPaul CantagrelPhilippe KerschenSebastien CabassonNicolas MaubeugeKarolina HankiewiczChantal NifleEric BergerHana MegherbiLaurent MagyFrederic KlapczynskiMariana Sarov RiviereClaire GiannesiniLorraine HamelinMarianne GirouxPierre BrangerAude MauroussetGuillaume MatheyMaximilien MoulinNicolas MéléCaroline PapeixRomain Marignier
• Organismes : Hôpital Fondation Adolphe de Rothschild = Adolphe de Rothschild Foundation Hospital Institut Toulousain des Maladies Infectieuses et Inflammatoires Centre Hospitalier Universitaire de Toulouse CHU Marseille Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale Service de neurologie [Bordeaux] CHU Pitié-Salpêtrière [AP-HP] Observatoire Français de la Sclérose En Plaques [Lyon] Hospices Civils de Lyon Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire [Rennes] = Rennes University Hospital [Pontchaillou] Centre d'Investigation Clinique [Rennes] Microenvironment and B-cells: Immunopathology, Cell Differentiation, and Cancer Service de Neurologie [CHU Nimes] Centre Hospitalier Régional Universitaire [CHU Lille] Lille Neurosciences & Cognition - U 1172 CHU Rouen Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Équipe Intégration Multisensorielle, Perception, Action et CogniTion - Integrative Multisensory Perception, Action and Cognition Team Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon) Centre Hospitalier de Luxembourg [Luxembourg]
• Publié dans Neurology le 01/11/2020

---

Résumé : Background and objectives: Because myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently identified autoimmune disorder, the natural history of MOGAD is still not well described. The objective of this study was to describe the long-term outcomes of adult patients with MOGAD. In addition, we aimed to identify factors affecting relapse risk and neurologic outcomes.Methods: Clinical and biological data were obtained from patients with a first event of MOGAD and included in the French nationwide incident cohort between February 2014 and March 2017. Only patients aged 18 years or older at disease onset and with observation period of at least 3 months were included. Data were collected prospectively until July 2023 and registered in the dedicated French nationwide database. This form includes every relapse with phenotype description during follow-up, date of last assessment, final clinical outcome with Expanded Disability Status Scale score and visual acuity, and maintenance therapy. The probability of recurrence-free survival was assessed using the Kaplan-Meier method.Results: We included 128 patients. The onset phenotype was isolated optic neuritis in 81 patients (63.3%) and isolated myelitis in 25 patients (19.5%). The median follow-up duration was 77.8 months (range 3.2-111.2), with 49 patients (38.3%) experienced at least one relapse. Median times from onset to second and third attacks were 3.2 (1.0-86.2) and 13.0 (2.6-64.4) months, respectively. At the last assessment, Expanded Disability Status Scale Score was ≥3 and ≥6 in 22 (17.2%) and 6 (4.7%) patients, respectively. Eighty patients received at least one maintenance treatment. This treatment was initiated after the first attack in 47 patients (36.7% of the whole cohort) and at the time of a second attack in 25 (19.5%). Multivariate analysis revealed that initiating maintenance treatment after the first attack was associated with a lower relapse risk (OR = 0.26 [95% CI 0.11-0.62], p = 0.002). In patients receiving maintenance therapy after first attack, the 2-year, 4-year, 6-year, and 8-year relapse risks were 11%, 15%, 20%, and 20%, respectively. In other patients, the risks were 41%, 46%, 51%, and 56%.Discussion: The highest risk of a relapse in MOGAD occurs early, and initiating maintenance therapy from the first attack substantially reduced the relapse risk.Classification of evidence: This study provides Class III evidence that initiating maintenance therapy from the first attack in patients with MOGAD reduces the relapse risk.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 09/08/2024
• Auteurs : Rabih AboukaisAntoine DevalckeneerPierre BoussemartPhilippe BourgeoisTomas MenovskyMartin BretznerMélodie-Anne KarnoubJean-Paul Lejeune
• Organismes : Thérapies Assistées par Lasers et Immunothérapies pour l'Oncologie - U 1189 Département de Neurochirurgie[Lille] Thérapies Assistées par Lasers et Immunothérapies pour l'Oncologie - U 1189 Département de Neurochirurgie[Lille] Centre Hospitalier Régional Universitaire [CHU Lille] Département de Neurochirurgie[Lille] Lille Neurosciences & Cognition - U 1172 Departement de Neuroradiologie [Lille] Département de Neurochirurgie[Lille] Thérapies Assistées par Lasers et Immunothérapies pour l'Oncologie - U 1189 Département de Neurochirurgie[Lille]
• Publié dans Neurosurgical Review le 01/11/2020

---

Résumé : Our study aimed to evaluate the postoperative outcome of patients with unruptured giant middle cerebral artery (MCA) aneurysm revealed by intracranial hypertension associated to midline brain shift. From 2012 to 2022, among the 954 patients treated by a microsurgical procedure for an intracranial aneurysm, our study included 9 consecutive patients with giant MCA aneurysm associated to intracranial hypertension with a midline brain shift. Deep hypothermic circulatory flow reduction (DHCFR) with vascular reconstruction was performed in 4 patients and cerebral revascularization with aneurysm trapping was the therapeutic strategy in 5 patients. Early (< 7 days) and long term clinical and radiological monitoring was done. Good functional outcome was considered as mRS score ≤ 2 at 3 months. The mean age at treatment was 44 yo (ranged from 17 to 70 yo). The mean maximal diameter of the aneurysm was 49 mm (ranged from 33 to 70 mm). The mean midline brain shift was 8.6 mm (ranged from 5 to 13 mm). Distal MCA territory hypoperfusion was noted in 6 patients. Diffuse postoperative cerebral edema occurred in the 9 patients with a mean delay of 59 h and conducted to a postoperative neurological deterioration in 7 of them. Postoperative death was noted in 3 patients. Among the 6 survivors, early postoperative decompressive hemicraniotomy was required in 4 patients. Good functional outcome was noted in 4 patients. Complete aneurysm occlusion was noted in each patient at last follow-up. We suggest to discuss a systematic decompressive hemicraniotomy at the end of the surgical procedure and/or a partial temporal lobe resection at its beginning to reduce the consequences of the edema reaction and to improve the postoperative outcome of this specific subgroup of patients. A better intraoperative assessment of the blood flow might also reduce the occurrence of the reperfusion syndrome.

---

Fichiers liés : s10143-024-02662-z.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 07/08/2024
• Auteurs : Bénédicte CaronPhilippe SeksikA. BuissonPauline WilsGuillaume SavoyeCarmen StefanescuDavid LaharieLucas GuilloVered AbitbolJoelle BonnetRomain AltweggLucine VuittonDriffa MoussataArnaud BourreilleAmélie BironCyrielle GillettaMathurin FumeryStephane NahonStéphane NanceyHouda CamaraLaurent Peyrin‐Biroulet
• Organismes : Nutrition-Génétique et Exposition aux Risques Environnementaux Centre Hospitalier Régional Universitaire de Nancy CHU Saint-Antoine [AP-HP] Centre de Recherche Saint-Antoine Service Hépato-Gastro-Entérologie [CHU Clermont-Ferrand] Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte Institute for Translational Research in Inflammation - U 1286 Centre Hospitalier Régional Universitaire [CHU Lille] Nutrition, Inflammation et axe Microbiote-Intestin-Cerveau Université de Rouen Normandie Service d'Hépato-Gastroentérologie [CHU Rouen] Clinique Ambroise Paré [Centres Médico-Chirurgicaux Ambroise Paré, Pierre Cherest, Hartmann] Hôpital Beaujon [AP-HP] Centre Hospitalier Universitaire de Bordeaux Hôpital Haut-Lévêque [CHU Bordeaux] Centre d'Investigation Clinique [Bordeaux] CHU Marseille Aix Marseille Université Hôpital Cochin [AP-HP] Hopital Saint-Louis [AP-HP] Département d'Hépato-Gastroentérologie et de Transplantation Hépatique [CHU Saint-Eloi] Centre Hospitalier Régional Universitaire de Besançon Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) Centre Hospitalier Régional Universitaire de Tours Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre d’Investigation Clinique de Nantes Hôpital universitaire Robert Debré [Reims] Service Gastroentérologie, hépatologie nutrition, diabétologie et maladies héréditaires du métabolisme pédiatrique [CHU Toulouse] Service d'Hépato Gastroenterologie [CHU Amiens-Picardie] Université de Picardie Jules Verne Groupe Hospitalier Intercommunal Le Raincy-Montfermeil Centre International de Recherche en Infectiologie Centre Hospitalier Lyon Sud [CHU - HCL] Autophagie infection et immunité - Autophagy Infection Immunity [CIRI] Centre Hospitalier Régional Universitaire de Nancy Centre Hospitalier Régional Universitaire de Nancy Nutrition-Génétique et Exposition aux Risques Environnementaux Research Institute of the McGill University Health Centre
• Publié dans Therapeutic Advances in Gastroenterology le 28/10/2020

---

Résumé : Background: Several adalimumab preparations are now available for patients with inflammatory bowel disease (IBD). Comparative satisfaction and tolerability are unknown. Objectives: This study investigated IBD patient satisfaction with approved adalimumab biosimilars and their originator. Design: In this cross-sectional study, we included 941 consecutive adalimumab-treated patients with IBD across 45 centres affiliated with the Groupe d’Etude Therapeutique des Affections Inflammatoires du tube Digestif who completed a satisfaction questionnaire comprising four items each rated by a 10-point scale. Methods: The differences in responses were performed using a one-way analysis of variance followed by Tukey’s honest significant difference test. Results: The most commonly used drugs at inclusion were Humira ® (436/941, 46.3%), Amgevita ® (177/941, 18.8%) and Hulio ® (105/941, 11.2%). The mean overall satisfaction rate with adalimumab was 8.5 (standard deviation 1.8). Overall satisfaction was significantly higher in patients treated with Humira (8.6 (1.5)), Hulio (8.6 (1.8)) or Amgevita (8.5 (1.4)) ( p < 0.05). Satisfaction with the subcutaneous injection form was higher for patients treated with Yuflyma ® (9.0 (1.4)), Humira (8.9 (1.3)) and Hulio (8.9 (1.7)) ( p < 0.05). A total of 299 patients (31.8%) described injection site reactions. In all, 223 patients (23.7%) reported being previously treated with another adalimumab of which (32/223, 14.3%) discontinued treatment due to side effects. Conclusion: In this real-world setting, patients with IBD had a high level of satisfaction with adalimumab treatment, with some differences in terms of overall satisfaction and satisfaction with the injection device.

---

Fichiers liés : caron-et-al-2024-patient-preferences-for-adalimumab-in-inflammatory-bowel-disease-a-nationwide-study-from-the-getaid.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 06/08/2024
• Auteurs : Vincent JonchèreHugo MontémontEnora Le ScanfAurélie SiretQuentin LetourneurEmmanuel TubacherChristophe BattailAssane FallKarim LabrecheVictor RenaultToky RatovomananaOlivier BuhardAriane JollyPhilippe Le RouzicCody FeysEmmanuelle DesprasHabib ZoualiRémy NicollePascale CerveraMagali SvrcekPierre BourgoinHélène BlanchéAnne BolandJérémie LefèvreYann ParcMehdi TouatFranck BielleDanielle ArzurGwennina CueffCatherine Le Jossic-CorcosGaël QuéréGwendal DujardinMarc BlondelCédric Le MaréchalRomain CohenThierry AndréFlorence CouletPierre de la GrangeAurélien de ReynièsJean-François FléjouFlorence RenaudAgusti AlentornLaurent CorcosJean-François DeleuzeAda ColluraAlex Duval
• Organismes : Site de recherche intégrée en cancérologie Centre de Recherche Saint-Antoine Site de recherche intégrée en cancérologie Site de recherche intégrée en cancérologie Site de recherche intégrée en cancérologie Site de recherche intégrée en cancérologie Fondation Jean Dausset - Centre d’Études du Polymorphisme Humain Centre National de Recherche en Génomique Humaine Site de recherche intégrée en cancérologie Site de recherche intégrée en cancérologie Fondation Jean Dausset - Centre d’Études du Polymorphisme Humain Site de recherche intégrée en cancérologie Site de recherche intégrée en cancérologie GenoSplice [Paris] Site de recherche intégrée en cancérologie Site de recherche intégrée en cancérologie Site de recherche intégrée en cancérologie Fondation Jean Dausset - Centre d’Études du Polymorphisme Humain Ligue Nationale Contre le Cancer - Paris Site de recherche intégrée en cancérologie AP-HP. Sorbonne Université Site de recherche intégrée en cancérologie AP-HP. Sorbonne Université Site de recherche intégrée en cancérologie AP-HP. Sorbonne Université Fondation Jean Dausset - Centre d’Études du Polymorphisme Humain Centre National de Recherche en Génomique Humaine Site de recherche intégrée en cancérologie AP-HP. Sorbonne Université Site de recherche intégrée en cancérologie AP-HP. Sorbonne Université Site de recherche intégrée en cancérologie Institut du Cerveau = Paris Brain Institute Génétique, génomique fonctionnelle et biotechnologies (UMR 1078) Génétique, génomique fonctionnelle et biotechnologies (UMR 1078) Génétique, génomique fonctionnelle et biotechnologies (UMR 1078) Génétique, génomique fonctionnelle et biotechnologies (UMR 1078) Génétique, génomique fonctionnelle et biotechnologies (UMR 1078) Génétique, génomique fonctionnelle et biotechnologies (UMR 1078) Génétique, génomique fonctionnelle et biotechnologies (UMR 1078) Site de recherche intégrée en cancérologie Sorbonne Université Site de recherche intégrée en cancérologie Sorbonne Université Site de recherche intégrée en cancérologie AP-HP. Sorbonne Université GenoSplice [Paris] Ligue Nationale Contre le Cancer - Paris Site de recherche intégrée en cancérologie AP-HP. Sorbonne Université Site de recherche intégrée en cancérologie Site de recherche intégrée en cancérologie Génétique, génomique fonctionnelle et biotechnologies (UMR 1078) Centre National de Recherche en Génomique Humaine Fondation Jean Dausset - Centre d’Études du Polymorphisme Humain Site de recherche intégrée en cancérologie Site de recherche intégrée en cancérologie
• Publié dans Genome Biology le 25/10/2020

---

Résumé : Background: Microsatellite instability (MSI) due to mismatch repair deficiency (dMMR) is common in colorectal cancer (CRC). These cancers are associated with somatic coding events, but the noncoding pathophysiological impact of this genomic instability is yet poorly understood. Here, we perform an analysis of coding and noncoding MSI events at the different steps of colorectal tumorigenesis using whole exome sequencing and search for associated splicing events via RNA sequencing at the bulk-tumor and single-cell levels.

Results: Our results demonstrate that MSI leads to hundreds of noncoding DNA mutations, notably at polypyrimidine U2AF RNA-binding sites which are endowed with cis-activity in splicing, while higher frequency of exon skipping events are observed in the mRNAs of MSI compared to non-MSI CRC. At the DNA level, these noncoding MSI mutations occur very early prior to cell transformation in the dMMR colonic crypt, accounting for only a fraction of the exon skipping in MSI CRC. At the RNA level, the aberrant exon skipping signature is likely to impair colonic cell differentiation in MSI CRC affecting the expression of alternative exons encoding protein isoforms governing cell fate, while also targeting constitutive exons, making dMMR cells immunogenic in early stage before the onset of coding mutations. This signature is characterized by its similarity to the oncogenic U2AF1-S34F splicing mutation observed in several other non-MSI cancer. Conclusions Overall, these findings provide evidence that a very early RNA splicing signature partly driven by MSI impairs cell differentiation and promotes MSI CRC initiation, far before coding mutations which accumulate later during MSI tumorigenesis.

---

Fichiers liés : 13059_2024_Article_3340.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 05/08/2024
• Auteurs : Cyril GrandjeanChristophe VéronésiChristine RusterucciCharlotte GautierYannis MaillotMaïté LeschevinFrançoise FournetJan DrouaudPaulo MarceloLuciane ZabijakP DelavaultP SimierSophie BoutonKarine Pageau
• Organismes : Institut Jean-Pierre Bourgin - Sciences du végétal Unité en Sciences Biologiques et Biotechnologies de Nantes BioEcoAgro-UPJV BioEcoAgro - Equipe 1 - Functioning and adaptation of the plant in interaction with its environment BioEcoAgro-UPJV BioEcoAgro - Equipe 1 - Functioning and adaptation of the plant in interaction with its environment BioEcoAgro - UMR transfrontalière INRAE 1158 BioEcoAgro-UPJV BioEcoAgro - UMR transfrontalière INRAE 1158 BioEcoAgro-UPJV BioEcoAgro - Equipe 1 - Functioning and adaptation of the plant in interaction with its environment BioEcoAgro-UPJV BioEcoAgro - Equipe 1 - Functioning and adaptation of the plant in interaction with its environment BioEcoAgro - UMR transfrontalière INRAE 1158 Plateforme d’Ingénierie Cellulaire et Analyses des Protéines - UPJV Plateforme d’Ingénierie Cellulaire et Analyses des Protéines - UPJV Unité en Sciences Biologiques et Biotechnologies de Nantes Unité en Sciences Biologiques et Biotechnologies de Nantes BioEcoAgro-UPJV BioEcoAgro - Equipe 1 - Functioning and adaptation of the plant in interaction with its environment BioEcoAgro-UPJV Université de Picardie Jules Verne BioEcoAgro - Equipe 1 - Functioning and adaptation of the plant in interaction with its environment
• Publié dans Plants le 27/10/2020

---

Résumé : Phelipanche ramosa is a root parasitic plant fully dependent on host plants for nutrition and development. Upon germination, the parasitic seedling develops inside the infected roots a specific organ, the haustorium, thanks to the cell wall-degrading enzymes of haustorial intrusive cells, and induces modifications in the host’s cell walls. The model plant Arabidopsis thaliana is susceptible to P. ramosa; thus, mutants in cell wall metabolism, particularly those involved in pectin remodeling, like Atpme3-1, are of interest in studying the involvement of cell wall-degrading enzymes in the establishment of plant–plant interactions. Host–parasite co-cultures in mini-rhizotron systems revealed that parasite attachments are twice as numerous and tubercle growth is quicker on Atpme3-1 roots than on WT roots. Compared to WT, the increased susceptibility in AtPME3-1 is associated with reduced PME activity in the roots and a lower degree of pectin methylesterification at the host–parasite interface, as detected immunohistochemically in infected roots. In addition, both WT and Atpme3-1 roots responded to infestation by modulating the expression of PAE- and PME-encoding genes, as well as related global enzyme activities in the roots before and after parasite attachment. However, these modulations differed between WT and Atpme3-1, which may contribute to different pectin remodeling in the roots and contrasting susceptibility to P. ramosa. With this integrative study, we aim to define a model of cell wall response to this specific biotic stress and indicate, for the first time, the role of PME3 in this parasitic plant–plant interaction.

---

Fichiers liés : plants-13-02168.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 02/08/2024
• Auteurs : Charles Champeaux-DepondSonia ZouaouiAmélie DarlixValérie RigauHélène Mathieu-DaudéFabienne BauchetMohamed KhettabBrigitte TrétarreDominique Figarella-BrangerLuc TaillandierJulien BoettoJohan PalludMatthieu PeyreMarine LottinLuc BauchetG. Abi LahoudR. AboukaisV. AchimT. AdetchessiB. AeschM. AghaN. AghakhaniR. Al HallakA. AlbertS. AldeaM. Ali BenaliY. AliV. AllanoM. AllaouiJ. AlliezF. AlmairacN. AouadF. ArthuisA. AshrafR. AssakerM. AttaJ. AuqueA. AutricqueA. BalossierJ. BaratM. BaronciniF. Barral-ClavelC. BarreyB. BatailleLuc BauchetX. BaujatB. BaussartM. BayramA. BazinY. BeaudicJ. BeaurainK. BeccariaG. BedouO. BekaertH. BelaidH. BelliardF. BellowR. BeltechiM. Ben IsmaïlA. BenazzaA. BenbrahiJ. BenezechL. Benhaddou-BenkiraneH. BenhimaM. BenmekhbiS. BennisM. BerhoumaC. BernardM. BernardA. BernatJ. BerthelotG BessonJérémy BillantR. Billon-GrandAhmad Al BitarC. BizetteJ. BlancA. BlanquetThomas BlauwblommeS. BlondE. BlondetA. BochJulien BoettoS. BoettoH. BoissonnetG. BonifaceE. BordA. BorhaC. BotellaI. BoualiS. BouazzaR. BougeardP. BouillotA. BourasP. BourgeoisJ. BousigueC. BousquetOlivier BousquetP. BousquetF. BoyerP. BoyerG. BrassierD. BraugeD. BressonBrie BrieJ. BrunonK. Buffenoir BilletN. BuissetP. CabalP. CaillaudF. CaireP. CamC. CaoCyrille CapelL. CapelleM. CardarelliL. CarlucciA. CarpentierR. CarronH. CebulaJ. CesariA. ChabaneS. ChabardesF. ChabolleR. ChaixCharles Champeaux DepondE. Chan SengD. ChaussemyD. ChauvetP. ChaynesA. ChaysJ. ChazalS. ChibbaroJ. ChirosselN. ChivoretM. ChoukriT. CivitS. ClemenceauH. CocaJ. CochereauGuillaume CollS. Colnat CoulboisP. CompaoreJ. CorneliusP. CornuD. CostacheA. CosteP. CoubesL. CrampetteA. CristiniE. CunyS. CureyA. CzornyG. D’acunziV. D’hardemareS. D’houtaudA. DagainP. Dam HieuJ. DandineI. DarieV. DarrouzetA. DautaM. DautheribesP. DavidB. de GermayF. de RoseT. de Saint-DenisJ. DebauxB. DebonoC. DebryA. DecouvelaereP. DecqO. DelalandeI. DelestretM. DelhayeM. DelionJ. DelmasA. DelmotteP. DelpyC. DelsantiJ. DerlonS. DerreyC. DesenclosM. DesgeorgesA. DesplatN. DesseP. DessiJ. DestandauChristophe DestrieuxB. DevauxE. DezamisP. DhellemmesL. Di TommasoS. DiabiraA. DiazC. DimitriuR. DjedidM. DjindjianL. DoK. DoeM. Dorel Le-TheG. DorfmullerD. Dorwling-CarterG. DranG. DuboisT. DudoitH. DuffauH. DufourT. DufourR. DuhemR. DulouB. DumasJ. DuntzeT. DupardM. DupuyA. DurandX. DussartreG. DutertreR. DuthelC. EapH. El FertitS. Elouahdani-HamdiE. EmeryJ. EngelhardtC. EspagnoP. EspositoR. FaguerT. FaillotW. FarahA. FaureP. FaureS. Ferrand SorbetsJ. FesseletA. FichtenD. FischerD. Fischer LokouD. FontaineM. FotsoD. FournierS. Fowo-NgadjouP. FrancoisB. FrankD. FrappazP. FregerE. Freitas OlimS. FreppelS. FroelichJ.-M. FuentesS. FuentesT. GaberelR. GadanS. GaillardF. GanemC. GantoisP. GauchezM. GayB. GeorgeR. GiacomelliM. GigaudS. Gil RoblesE. GimbertC. GingueneO. GoasguenJ. GodardG. GodfrinA. GomezV. Gonzalez MartinezP. GossetG. GouelloS. GoutagnyThomas GraillonG. Gras CombeM. GrassiB. GrayeliM. GrelatP. GrellierF. GrisoliJ. GuarnieriGuedon GuedonY. GueganM. GuenotD. Guerra SierraE. GueyeM. GurshiJ. GuyotatE. HaddadC. HaegelenS. HamdiO. HamelA. HamlatP. HannequinF. Hansen von BunauO. HatemG. HayekA. HerbrechtP. HermanJ. HladkyX. HoarauD. HoffmannC. HorodyckidJ. HuotG. IakovlevR. IbrahimB. IrthumR. IschacTimothée JacquessonG. JacquetS. JamesM. JanB. JarrayaVincent JeckoE. JouanneauA. JoudT. JulhienH. KaddoumM. KalamaridesC. KarachiH. KatrangiJ. KayaP. KehrliY. KeravelM. KhalfallahI. KhalilT. KhalilK. KhouriS. KhouriJ. KleiberO. KleinA. KoudsieW. KrichenA. KuzeawuG. LabordeL. LaccoureyeJ. LagarrigueD. LaguerreM. LahianiM. LahlouO. LangloisF. LapierreC. LaprasLascu LascuO. LaunayJ. LavieilleM. Le CorreLe Fay Le FayM. Le FrancC. Le GuerinelP. LefevreD. LegarsJoseph LejeuneJ. LemaireG. LenaJ. LepeintreB. LericheH. LeroyJ. LescureJ. LestonM. LevequeD. LiguoroE. LioretAnne ListratF. LitreS. LitricoH. LoiseauM. LonjonN. LonjonM. LopesJ. LoretG. LotE. LouisA. LouveauV. LubranoF. LucasO. LucasG. LunguJ. MaarrawiC. MagheruE. MagroJ. Maheut-LourmiereK. MahlaA. MaillardM. MaingotD. MaitrotO. MakieseS. MandatE. MandonnetR. ManetMansour MansourN. ManzoJ. MarchalJ. MarieP. MarinhoD. MarnetA. MarnicheC. MartinS. MartinA. MelotD. Memia ZoloV. Mendes MartinsD. MenegalliP. MeneiP. MercierI. MerlotP. MertensM. MessererP. MetellusV. Meyer-BischM. MeyerJ. MineoE. MireauO. MollierP. MonteilR. MontessuyA. MoraX. MorandiS. MorarC. MoraruJ. MoreauC. MorelJ. MortadaK. MostofiC. MottoleseK. MoubarakL. MourierE. MoyseB. MuckensturmElie NaderF. NahasH. NamakiK. NarantuyaFrédéric NatafS. NavarroJ. NguyenT. NjeeL. NoguesR. NoudelA. NouetR. NseirC. NutiM. OrabiD. OrensteinY. OuammouN. OuerchefaniP. PageS. PalfiJohan PalludO. PalombiP. PaquisG. Paradot MoutonF. ParkerJ. PassagiaG. PaternosterG. Pech GourgI. Pelissou-GuyotatJ. PeltierP. PencaletP. PencaletG. PenchetJ. PeragutA. PerezPascal PernotG. PerrinH. PersonP. PeruzziA. PetitD. PetitMathieu PeyreN. PimentaC. PinelliB. PiotB. PlasJ. PlasG. PoloC. PopaC. PopaV. PorhielA. PostelnicuB. PouitP. VincentJ. PrivatF. ProustA. Pruvot-OcceanS. PugetC. RabehenoinaM. RabhiO. RagraguiT. RambolarimananaRanchere RanchereS. RaoulD. RasendrarijaoF. RechA. RedondoJ. RegisV. ReinaRemond RemondJ. RemondY. ReynierN. ReynsA. Ricci FranchiA. RichetF. RicouartT. RiegelT. RiemL. RiffaudP. RigoardG. RobertR. RobertA. RobierP.-H. RocheM.-A. RodriguezV. RodriguezM. RosG. RoualdesV. RoualdesA. RougierT. RoujeauP. RousseauxF. RouxF. RouxM. RuéJ. SabatierP. SabatierM. SabbahO. SackoC. Sainte-RoseL. SakkaC. SalaudH. SalleB. SalmonF. San GalliJ. SankaredjaJ. SautreauxF. SauvagetP. ScaroneD. ScavardaB. ScherpereelE. SchmidtF. SegnarbieuxE. SeigneuretR. SeizeurL. SelekJ. SichezS. Sid HamedF. SignorelliB. SilhouetteA. SimonE. SimonA. SimonneauD. SinardetM. SindouM. SleimanJérôme SolO. SoumareA. SrourR. SrourH. StaquetJ. SteckenI. StellaO. SterkersB. StilhartA. SzathmariS. TahaS. TaziJ. TernierO. TestaM. TetardE. TheretJ. ThiebautL. ThinesC. ThomasJ. ThomassinL. TiganA. TimofeevA. Tobenas DujardinJ. TodeschiV. TonnelleH. TourneuxP. ToussaintA. ToutaP. Tran Ba HuyNicolas TraversM. TremouletB. TurakB. ValleeP. VallyR. van EffenterreY. van RaayF. VaneeclooF. VassalM. VassalS. VelutJulie VidalJ. VignesL. VilletteA. VincentelliM. VinchonL. VinikoffJ. VoirinM. WagerY. YordanovaF. ZaïriIlyess ZemmouraM. ZerahJ. ZiyadehC. AdamH. Adle-BiassetteP. AlemanyM. AlgrosCorine AmatM. AndraudF. AndreiuoloF. AnsartF. Arbez-GindreF. ArbionP. ArrivetsC. AttencourtStéphane AubertM. Aubriot LortonG. AverousJ. AzizaA. BadsiA. BaglinP. BaldetX. BarVirginie BarasC. BarbeyA. BayC. BazilleI. BedgedjianP. BedossaS. BenabidallahA. BenaliA. Bergemer FouquetM. BergouignanC. Bernard-DecotM. BernierC. BertocchiF. BeuvonFranck BielleC. BillotetP. BirembautS. BisiauC. BlechetL. BondoinC. BonneauG. BonyhayX. BordierS. BoudjadiC. Boulagnon-RombiJ. BoutonnatC. BouvierE. BrambillaD. BranquetF. BreibachA. BressenotC. BrocheA. BrouchetJ. BroulandP. BroussetCabrol CabrolV. CahnP. CalvetJ. CamoP. CamparoC. CapuaniE. CassagnauJ. CasseD. CathelineauS. CauletP. CaveriviereD. Cazals-HatemM. ChambonniereF. ChaponF. CharlotteD. ChatelainM. ChenardX. ChevalierD. ChiforeanuF. ChretienC. ChristovA. ClairotteC. CohenV. Conan-CharletX. ConchaC. CordonnierB. CormierK. CostaSandrine CostaN. Costes-CharletV. CostesAurélie CoulonA. CouvelardA. CroueT. CruelX. DagM. DanjouxD. DarrasseC. Daumas-DuportM. DelM. Delage CorreF. DelalandeC. DelfourC. DelfourM. DelisleM. DelsolM. Denis-MusquerLaure Burel-DeschampsV. DesestretM. DesrousseauxM. DieboldA. DonsbeckN. DreuxL. Droy-DupreGaspard DubostM. DuchesneH. DucoinO. DudezI. DugaJ. DumollardL. DurandC. DusorbierL. DusserreH. DuvalS. EimerW. El Alami-ThomasY. ElouaretG. EscourrouC. EtchandyR. EyremandiP. FabriceC. Fallet-BiancoB. Faroy MenciereM. Felce DachezS. FelixC. FernandezF. FetissofC. FeutryDominique Figarella-BrangerC. FleuryAllyx FontaineF. ForestP. FornesB. FouetM. FregevilleG. FromontC. GaspardG. GauchotteG. GayC. GodfraindM. GontierS. GonzalezJean-Philippe GoujonF. GrayP. GrosP. GuillouC. GuiryJ. HarimenshiA. HeitzmannD. HeninV. HennequinM. HeymannJ. IkoliL. IstierJ. JazeronM. JeantetA. JouvetC. Kandel-AznarB. KantelipKemeny KemenyO. KerdraonR. KerdraonH. KermanacA. KhaddageI. KleinclausS. KrzischM. KujasF. LabrousseC. LacroixL. LamantS. LantuejoulA. LaquerriereM. Laurent-YriarteC. LaurentF. LegallM. Le HoucqC. Le Naoures-MealE. LechaptF. LeclairLeclercq LeclercqC. LecointreF. LegerS. LepreuxF. LerintiuP. LevillainB. LhermitteA. LiprandiF. LlamasK. LlinaresE. LongchamptD. LoussouarnM. MachetF. MaitreE. Majek-ZakineA. ManentA. MaranL. MarcellinAntoine MarchalN. MarconP. MarcorellesA. MareelC. MarguetB. MarieL. MartinMathieu Mag GalloA. de MauespaulaC. MaurageC. MazerollesA. MensahE. MergeyD. MeyronetS. MichalakJ. MichelsP. MichenetJ. MichielsI. Mihlai MarcelaS. MilinC. MiquelManuela MohrK. MokhtariC. MondonC. Monegier Du SorbierI. Morand DusserreA. MoreauM. MoreauJ. MosnierC. Musso RigalK. MyrmelI. N GuyenA. NeuvilleA. OksmanM. OneaMarielle PagesJ. PalasseM. PateyJ. PellissierM. Peoc’hT. PetrellaA. PhilippeJ. PialatM. PluotM. PolivkaI. PommepuyM. PradereF. ProjettiM. QuintanaI. QuintinM. Quintyn-RantyJ. RamosE. RanfaingD. RaouxP. RaynaudR. Reis BorgesF. RenaudL. RenjardJ. ReyreP. RichardS. RichardValérie RigauF. RingenbachB. RiviereP. RogerI. RouquetteA. RousseauMorgane RousseletC. RousselotJ. SabourinV. SaguetS. SaïkaliM. Saint-PaulG. Saint PierreC. SalonL. SamaisonC. SavinJ. SelvesP. SeuratH. SevestreC. SingeorzanR. SorbaraR. SoulardJ. SouraudP. Sto StraubN. StreichenbergerN. SturmV. SzablewskiM. TalagasM. TarisA. Tauziede-EspariatN. ThiC. ToquetM. TortelG. ToubeauE. TournierE. Uro-CosteS. Valmary DeganoF. VandenbosP. VarletA. VasiljevicL. VeresezanP. VerhulstG. ViennetJ. VignaudC. VigourouxC. VillaA. VitalA. WarterM. WassefN. WeinbreckM. YacoubD. ZacharM. Zidane Marinnes
• Organismes : Hôpital Privé Clairval [Marseille] Neurochirurgie [Hôpital Gui de Chauliac] Institut de Génomique Fonctionnelle Institut de Génomique Fonctionnelle Institut régional de Cancérologie de Montpellier Institut de Génomique Fonctionnelle Hôpital Gui de Chauliac [CHU Montpellier] Registre des Tumeurs de l'Hérault Institut régional de Cancérologie de Montpellier Registre des Tumeurs de l'Hérault Institut régional de Cancérologie de Montpellier Centre Hospitalier Universitaire de La Réunion Université de La Réunion Equipe EQUITY (CERPOP) Réseau des registres français du cancer Registre des Tumeurs de l'Hérault Institut de neurophysiopathologie Service de neurologie [CHRU Nancy] Neurochirurgie [Hôpital Gui de Chauliac] Institut de Génomique Fonctionnelle Institut de psychiatrie et neurosciences de Paris Groupe hospitalier universitaire Paris psychiatrie & neurosciences [Paris] CHU Pitié-Salpêtrière [AP-HP] Institut du Cerveau = Paris Brain Institute CHU Amiens-Picardie Neurochirurgie [Hôpital Gui de Chauliac] Institut de Génomique Fonctionnelle Thérapies Assistées par Lasers et Immunothérapies pour l'Oncologie - U 1189 Hôpital de la Timone [CHU - APHM] Hôpital Bicêtre [GHU AP-HP. Université Paris-Saclay, Le Kremlin-Bicêtre] Institut Pluridisciplinaire Hubert Curien Université de Haute-Alsace (UHA) Mulhouse - Colmar CHU Rothschild [AP-HP] Université Côte d'Azur Hôpital Pasteur [Nice] University of Science and Technology of China [Hefei] Protéomique, Réponse Inflammatoire et Spectrométrie de Masse (PRISM) - U 1192 Laboratoire de Chimie et Biologie des Métaux Université Henri Poincaré - Nancy 1 Institut de Recherche sur la Fusion par confinement Magnétique Hôpital Privé Clairval [Marseille] Lille Neurosciences & Cognition - U 1172 Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Ecole Nationale Supérieure d'Arts et Métiers [Cluny] Institut Charles Gerhardt Montpellier - Institut de Chimie Moléculaire et des Matériaux de Montpellier Neurochirurgie [Hôpital Gui de Chauliac] Institut de Génomique Fonctionnelle Hôpital Foch [Suresnes] Analyse Bio-Informatique pour la Génomique et le Métabolisme Service de neurochirurgie [CHU Dijon] Hôpital Necker - Enfants Malades [AP-HP] Éco-Anthropologie Imagine - Institut des maladies génétiques (IHU) GHU AP-HP Centre Université Paris Cité Service de Neurochirurgie pédiatrique, Hôpital Necker-Enfants Malades, APHP Neurochirurgie [Hôpital Gui de Chauliac] Institut de Génomique Fonctionnelle Hôpital Privé Clairval [Marseille] Centre de Recherches en Cancérologie de Toulouse Molécules de Communication et Adaptation des Micro-organismes BioArchéologie, Interactions Sociétés Environnements University of Aberdeen Statistical Inference for Structural Health Monitoring Département de neurochirurgie [Angers] Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes-Angers Institut de psychiatrie et neurosciences de Paris Groupe hospitalier universitaire Paris psychiatrie & neurosciences [Paris] CHU Pitié-Salpêtrière [AP-HP] Institut du Cerveau = Paris Brain Institute Service de Neurochirurgie [CHRU de Tours] Imaging, Brain & Neuropsychiatry Service de neurochirurgie [CHU Marseille] Imaging, Brain & Neuropsychiatry Service de Neurochirurgie [CHRU de Tours] FLUOREM Laboratoire de Mecanique des Fluides et d'Acoustique Institut de neurophysiopathologie Station biologique de Roscoff = Roscoff Marine Station Laboratoire d'études en Géophysique et océanographie spatiales Institut de Génomique Fonctionnelle Hôpital Gui de Chauliac [CHU Montpellier] Sorbonne Université CHU Saint-Antoine [AP-HP] Centre de Recherche Saint-Antoine
• Publié dans Acta Neurochirurgica le 25/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2024
• Auteurs : Hayet BaoucheCécile CouchoudHenri BoulangerSalima Ahriz-SaksiImene MansouriAbdelaziz HamaniPierre TaupinXavier FerreiraMarine PanayeJulien J. StirnemannOlivier MoranneJean-Philippe Jais
• Organismes : Service d'informatique médicale et biostatistiques [CHU Necker] Chronic Kidney Disease - Réseau Epidémiologie et Information en Néphrologie Chronic Kidney Disease - Réseau Epidémiologie et Information en Néphrologie Agence de la biomédecine [Saint-Denis la Plaine] Clinique de l'Estrée Clinique de l'Estrée Chronic Kidney Disease - Réseau Epidémiologie et Information en Néphrologie Agence de la biomédecine [Saint-Denis la Plaine] Service d'informatique médicale et biostatistiques [CHU Necker] Service d'informatique médicale et biostatistiques [CHU Necker] Hôpital Edouard Herriot [CHU - HCL] Fédération pour la recherche en explorations et thérapeutiques innovantes in utéro Service de maternité [CHU Necker] Centre Hospitalier Universitaire de Nîmes Institut Desbrest d'Epidémiologie et de Santé Publique Service d'informatique médicale et biostatistiques [CHU Necker] Chronic Kidney Disease - Réseau Epidémiologie et Information en Néphrologie Fédération pour la recherche en explorations et thérapeutiques innovantes in utéro
• Publié dans Kidney International Reports le 26/10/2020

---

Résumé : Introduction: In women receiving chronic dialysis, fertility is impaired. The objectives of this study were to estimate the incidence rate of pregnancies among women of childbearing age (15–50 years) receiving chronic dialysis from 2006 to 2020 in France, to describe the pregnancy outcomes and renal management during pregnancy. Methods: This national observational, retrospective study was based on data from the French REIN registry matched with the National Health Data System. Results: Over the period 2006 to 2020 in France, 348 pregnancies were identified in 240 women receiving chronic dialysis. The overall incidence of pregnancy was 11.1, 95% confidence interval (CI) (9.9–12.3) cases per 1000 person-years. Hemodialysis was the predominant modality during pregnancy. Main maternal complications were preeclampsia (n = 19) and gestational diabetes (n = 11). The most obstetric complications were premature rupture of membranes (n = 14) and polyhydramnios (n = 5). These pregnancies resulted in 174 (50%) abortions (<22 weeks), including 104 elective abortions (29.9%), 44 miscarriages (12.6%), 17 therapeutic abortions (4.9%), 5 ectopic pregnancies (1.4%), and 4 hydatidiform moles (1.2%). The remaining 174 (50%) pregnancies with deliveries (≥22 weeks) resulted in 166 live births (70 full-term [42.2%], 96 preterm births [57.8%]), and 8 stillbirths. Median gestational age was 36 weeks (32–38) for 174 deliveries. Conclusion: There have been improvements in maternal and fetal outcomes regarding pregnancy on chronic dialysis. However, our study shows a significant proportion of elective abortions. Better fertility management of women receiving chronic dialysis is advised by contraception or by pregnancy planning and early multidisciplinary follow-up.

---

Fichiers liés : 1-s2.0-S2468024924017169-main.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2024
• Auteurs : Eugeni BeldaJacqueline CapeauJean-Daniel ZuckerEmmanuelle Le ChatelierNicolas PonsFlorian Plaza OñateBenoit QuinquisRohia AliliSoraya FellahiChristine KatlamaKarine ClémentBruno FèveStéphane JaureguiberryCécile GoujardOlivier LambotteJoël DoréEdi PriftiJean-Philippe Bastard
• Organismes : Unité de modélisation mathématique et informatique des systèmes complexes [Bondy] Nutrition et obésités: approches systémiques (UMR-S 1269) Centre de Recherche Saint-Antoine Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] Unité de modélisation mathématique et informatique des systèmes complexes [Bondy] Nutrition et obésités: approches systémiques (UMR-S 1269) MetaGenoPolis MetaGenoPolis MetaGenoPolis MetaGenoPolis Nutrition et obésités: approches systémiques (UMR-S 1269) Lipodystrophies, adaptations métaboliques et hormonales, et vieillissement [CRSA] Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] CHU Tenon [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP] Nutrition et obésités: approches systémiques (UMR-S 1269) CHU Pitié-Salpêtrière [AP-HP] CHU Saint-Antoine [AP-HP] Centre de Recherche Saint-Antoine Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] GHU AP-HP. Université Paris Saclay Hôpital Bicêtre [GHU AP-HP. Université Paris-Saclay, Le Kremlin-Bicêtre] Hôpital Bicêtre [GHU AP-HP. Université Paris-Saclay, Le Kremlin-Bicêtre] Centre de recherche en épidémiologie et santé des populations UFR Sciences de la santé Simone Veil Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes MetaGenoPolis MICrobiologie de l'ALImentation au Service de la Santé Unité de modélisation mathématique et informatique des systèmes complexes [Bondy] Nutrition et obésités: approches systémiques (UMR-S 1269) IMRB - SMCD/"Senescence, Metabolism and Cardiovascular Diseases" [Créteil] CHU Henri Mondor [Créteil] Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière]
• Publié dans BMC Medical Genomics le 23/10/2020

---

Résumé : Persons living with HIV (PWH) harbor an altered gut microbiome (higher abundance of Prevotella and lower abundance of Bacillota and Ruminococcus lineages) compared to non-infected individuals. Some of these alterations are linked to sexual preference and others to the HIV infection. The relationship between these lineages and metabolic alterations, often present in aging PWH, has been poorly investigated. In this study, we compared fecal metagenomes of 25 antiretroviral-treatment (ART)-controlled PWH to three independent control groups of 25 non-infected matched individuals by means of univariate analyses and machine learning methods. Moreover, we used two external datasets to validate predictive models of PWH classification. Next, we searched for associations between clinical and biological metabolic parameters with taxonomic and functional microbiome profiles. Finally, we compare the gut microbiome in 7 PWH after a 17-week ART switch to raltegravir/maraviroc. Three major enterotypes (Prevotella, Bacteroides and Ruminococcaceae) were present in all groups. The first Prevotella enterotype was enriched in PWH, with several of characteristic lineages associated with poor metabolic profiles (low HDL and adiponectin, high insulin resistance (HOMA-IR)). Conversely butyrate-producing lineages were markedly depleted in PWH independently of sexual preference and were associated with a better metabolic profile (higher HDL and adiponectin and lower HOMA-IR). Accordingly with the worst metabolic status of PWH, butyrate production and amino-acid degradation modules were associated with high HDL and adiponectin and low HOMA-IR. Random Forest models trained to classify PWH vs. control on taxonomic abundances displayed high generalization performance on two external holdout datasets (ROC AUC of 80-82%). Finally, no significant alterations in microbiome composition were observed after switching to raltegravir/maraviroc. High resolution metagenomic analyses revealed major differences in the gut microbiome of ART-controlled PWH when compared with three independent matched cohorts of controls. The observed marked insulin resistance could result both from enrichment in Prevotella lineages, and from the depletion in species producing butyrate and involved into amino-acid degradation, which depletion is linked with the HIV infection.

---

Fichiers liés : s12920-024-01978-5.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2024
• Auteurs : Ronny LauerwaldAna BastosMatthew J McgrathAna Maria Roxana PetrescuFrançois RitterRobbie M AndrewAntoine BerchetGrégoire BroquetDominik BrunnerFrederic ChevallierAlessandro CescattiSara FilipekAudrey Fortems‐cheineyGiovanni ForzieriPierre FriedlingsteinRichard FuchsChristoph GerbigSander HouwelingPiyu KeBas Jan Willem LerinkWanjing LiWei LiXiaojun LiIngrid T LuijkxGuillaume MonteilSaqr MunassarGert‐jan NabuursPrabir K. PatraP. PeylinJulia PongratzPierre RegnierMarielle SaunoisMart‐jan SchelhaasMarko ScholzeStephen SitchRona L ThompsonHanqin TianAki TsurutaChristopher WilsonJean‐pierre WigneronYitong YaoSönke ZaehlePhilippe Ciais
• Organismes : Université Paris-Saclay Ecologie fonctionnelle et écotoxicologie des agroécosystèmes Max-Planck-Institut für Biochemie = Max Planck Institute of Biochemistry Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] Vrije Universiteit Amsterdam [Amsterdam] Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] Modélisation INVerse pour les mesures atmosphériques et SATellitaires Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] Modélisation INVerse pour les mesures atmosphériques et SATellitaires Interactions Sol Plante Atmosphère Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] Modélisation des Surfaces et Interfaces Continentales Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] Modélisation INVerse pour les mesures atmosphériques et SATellitaires Interactions Sol Plante Atmosphère
• Publié dans Global Biogeochemical Cycles le 25/10/2020

---

Résumé : In the framework of the RECCAP2 initiative, we present the greenhouse gas (GHG) and carbon (C) budget of Europe. For the decade of the 2010s, we present a bottom-up (BU) estimate of GHG netemissions of 3.9 Pg CO 2 -eq. yr 1 (using a global warming potential on a 100 years horizon), which are largely dominated by fossil fuel emissions. In this decade, terrestrial ecosystems acted as a net GHG sink of 0.9 Pg CO 2 -eq. yr 1 , dominated by a CO 2 sink that was partially counterbalanced by net emissions of CH 4 and N 2 O. For CH 4 and N 2 O, we find good agreement between BU and top-down (TD) estimates from atmospheric inversions. However, our BU land CO 2 sink is significantly higher than the TD estimates. We further show that decadal averages of GHG net-emissions have declined by 1.2 Pg CO 2 -eq. yr 1 since the 1990s, mainly due to a reduction in fossil fuel emissions. In addition, based on both data driven BU and TD estimates, we also find that the land CO 2 sink has weakened over the past two decades. A large part of the European CO 2 and C sinks is located in Northern Europe. At the same time, we find a decreasing trend in sink strength in Scandinavia, which can be attributed to an increase in forest management intensity. These are partly offset by increasing CO 2 sinks in parts of Eastern Europe and Northern Spain, attributed in part to land use change. Extensive regions of high CH 4 and N 2 O emissions are mainly attributed to agricultural activities and are found in Belgium, the Netherlands and the southern UK. We further analyzed interannual variability in the GHG budgets. The drought year of 2003 shows the highest net-emissions of CO 2 and of all GHGs combined.

---

Fichiers liés : Global Biogeochemical Cycles - 2024 - Lauerwald - Carbon and Greenhouse Gas Budgets of Europe Trends Interannual and.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2024
• Auteurs : Valentin GoutaudierRichard DangerRusan Ali CatarMaud RacapéAurélie PhilippeMichelle EliasMarc RaynaudOlivier AubertDidier BoutonFrançois GirardinÉric VicautSarhan YaicheJacques DemotesHarald HeideckeJean-Luc TaupinChristine Randoux-LebrunMohamad ZaidanEmmanuelle PapuchonHoa Le MaiThi van Ha NguyenFrancesc MoresoThierry BerneyJean VillardChristophe LegendreDuska DragunVassilios PapaloisLuciano PotenaMagali GiralPierre-Antoine GourraudSophie BrouardElena CrespoFabian HalleckKlemens BuddeOriol BestardAlexandre LoupyCarmen Lefaucheur
• Organismes : Paris-Centre de Recherche Cardiovasculaire Hôpital Necker - Enfants Malades [AP-HP] Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology Team 4 : Deciphering organ immune regulation in inflammation and transplantation (DORI-t) Institut de Transplantation et de Recherche en Transplantation [CHU Nantes] Berlin Institute of Health Charité - UniversitätsMedizin = Berlin University Medicine Paris-Centre de Recherche Cardiovasculaire Laboratoire Universitaire de Biodiversité et Ecologie Microbienne Hopital Saint-Louis [AP-HP] Paris-Centre de Recherche Cardiovasculaire Paris-Centre de Recherche Cardiovasculaire Hôpital Necker - Enfants Malades [AP-HP] Assistance publique - Hôpitaux de Paris (AP-HP) Laboratoire Vibrations Acoustique centre Lyonnais d'Acoustique Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [AP-HP] Université Paris Cité Service d'Immunologie et d'Histocompatibilité Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [AP-HP] Hôpital Bicêtre [GHU AP-HP. Université Paris-Saclay, Le Kremlin-Bicêtre] Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology Institut de Transplantation et de Recherche en Transplantation [CHU Nantes] Team 4 : Deciphering organ immune regulation in inflammation and transplantation (DORI-t) Team 4 : Deciphering organ immune regulation in inflammation and transplantation (DORI-t) Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology Institut de Transplantation et de Recherche en Transplantation [CHU Nantes] Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology Team 4 : Deciphering organ immune regulation in inflammation and transplantation (DORI-t) Institut de Transplantation et de Recherche en Transplantation [CHU Nantes] Vall d'Hebron University Hospital [Barcelona] Hôpitaux Universitaires de Genève = University Hospital of Geneva [Genève] Hôpitaux Universitaires de Genève = University Hospital of Geneva [Genève] Service de néphrologie adultes [CHU Necker] Charité - UniversitätsMedizin = Berlin University Medicine Humboldt-Universität zu Berlin = Humboldt University of Berlin = Université Humboldt de Berlin Berlin Institute of Health Hammersmith Hospital NHS Imperial College Healthcare IRCCS Azienda Ospedaliero-Universitaria di Bologna Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology Team 4 : Deciphering organ immune regulation in inflammation and transplantation (DORI-t) Institut de Transplantation et de Recherche en Transplantation [CHU Nantes] Team 3 : Integrative transplantation, HLA, Immunology and genomics of kidney injury Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology Institut de Transplantation et de Recherche en Transplantation [CHU Nantes] Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology Team 4 : Deciphering organ immune regulation in inflammation and transplantation (DORI-t) Institut de Transplantation et de Recherche en Transplantation [CHU Nantes] Vall d'Hebron Research Institute - Institut de Recerca Vall d’Hebron Charité - UniversitätsMedizin = Berlin University Medicine Humboldt-Universität zu Berlin = Humboldt University of Berlin = Université Humboldt de Berlin Berlin Institute of Health Charité - UniversitätsMedizin = Berlin University Medicine Humboldt-Universität zu Berlin = Humboldt University of Berlin = Université Humboldt de Berlin Berlin Institute of Health Vall d'Hebron University Hospital [Barcelona] Paris-Centre de Recherche Cardiovasculaire Service de néphrologie adultes [CHU Necker] Paris-Centre de Recherche Cardiovasculaire Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [AP-HP]
• Publié dans Kidney International le 27/10/2020

---

Résumé : Non-invasive biomarkers are promising tools for improving kidney allograft rejection monitoring, but their clinical adoption requires more evidence in specifically designed studies. To address this unmet need, we designed the EU-TRAIN study, a large prospective multicentric unselected cohort funded by the European Commission. Here, we included consecutive adult patients who received a kidney allograft in nine European transplant centers between November 2018 and June 2020. We prospectively assessed gene expression levels of 19 blood messenger RNAs, four antibodies targeting non-human leukocyte antigen (HLA) endothelial antigens, together with circulating anti-HLA donor-specific antibodies (DSA). The primary outcome was allograft rejection (antibody-mediated, T cell-mediated, or mixed) in the first year post-transplantation. Overall, 412 patients were included, with 812 biopsies paired with a blood sample. CD4 gene expression was significantly associated with rejection, while circulating anti-HLA DSA had a significant association with allograft rejection and a strong association with antibody-mediated rejection. All other tested biomarkers, including AKR1C3, CD3E, CD40, CD8A, CD9, CTLA4, ENTPD1, FOXP3, GZMB, ID3, IL7R, MS4A1, MZB1, POU2AF1, POU2F1, TCL1A, TLR4, and TRIB1, as well as antibodies against angiotensin II type 1 receptor, endothelin 1 type A receptor, C3a and C5a receptors, did not show significant associations with allograft rejection. The blood messenger RNAs and non-HLA antibodies did not show an additional value beyond standard of care monitoring parameters and circulating anti-HLA DSA to predict allograft rejection in the first year post-transplantation. Thus, our results open avenues for specifically designed studies to demonstrate the clinical relevance and implementation of other candidate non-invasive biomarkers in kidney transplantation practice.

---

Fichiers liés : PIIS0085253824005659.pdf

---

Source